Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Daratumumab and Ibrutinib for Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT)

NCT04230304 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04230304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04230304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Daratumumab and Ibrutinib for Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
November 11, 2020
Completion date
February 13, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent chronic lymphocytic leukemia, recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, refractory small lymphocytic lymphoma